Mumbai, June 22, 2017: Alembic Pharmaceuticals has received US Food and Drug Administration (USFDA) approval for its Abbreviated New Drug Application (ANDA) for Candesartan Cilexetil Tablets, 32 mg.
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Atacand Tablets, 32 mg of AstraZeneca Pharmaceuticals LP. Candesartan Cilexetil Tablets are indicated for treatment of hypertension in adults and children and treatment of heart failure (NYHA class II-IV).
Candesartan Cilexetil Tablets, 32mg have an estimated market size of USD 27 million for twelve months ending December 2016, according to IMS.
United News of India
-An 11-year-old boy from Yemen and a 34-year-old man from Bengaluru, both suffered from end-stage…
Mumbai, 14th May 2024 – As part of its dedication to exceptional patient care, American Oncology…
Mumbai, May 11, 2024: In a landmark move for Indian healthcare, the introduction of Second…
Bengaluru, May 08, 2024: Cancer remains the illness most feared across the globe. But to combat…
- This specialized division empowers patients with neurological disorders to reclaim their mobility through a…
SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…